Literature DB >> 20185182

Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia.

Diego Novick1, Josep Maria Haro, David Suarez, Victor Perez, Ralf W Dittmann, Peter M Haddad.   

Abstract

To assess baseline predictors and consequences of antipsychotic adherence during the long-term treatment of schizophrenia outpatients, data were taken from the 3-year, prospective, observational, European Schizophrenia Outpatients Health Outcomes (SOHO) study, in which outpatients starting or changing antipsychotics were assessed every 6 months. Physician-rated adherence was dichotomized as adherence/non-adherence. Regression models tested for predictors of adherence during follow-up, and associations between adherence and outcome measures. Of the 6731 patients analysed, 71.2% were adherent and 28.8% were non-adherent over 3 years. The strongest predictor of adherence was adherence in the month before baseline assessment. Other baseline predictors of adherence included initial treatment for schizophrenia and greater social activities. Baseline predictors of non-adherence were alcohol dependence and substance abuse in the previous month, hospitalization in the previous 6 months, independent housing and the presence of hostility. Non-adherence was significantly associated with an increased risk of relapse, hospitalization and suicide attempts. In conclusion, non-adherence is common but can partly be predicted. This may allow strategies to improve adherence to be targeted to high-risk patients. Also, reversal of some risk factors may improve adherence. Non-adherence is associated with a range of poorer long-term outcomes, with clinical and economic implications. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185182     DOI: 10.1016/j.psychres.2009.05.004

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  132 in total

Review 1.  The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values.

Authors:  Lik Hang N Lee; Charles Choi; Abby C Collier; Alasdair M Barr; William G Honer; Ric M Procyshyn
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

Review 2.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

3.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

4.  Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability.

Authors:  Sourabh Moti Singh; Peter M Haddad; Nusrat Husain; Eamonn Heaney; Barbara Tomenson; Imran B Chaudhry
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-10

5.  Does Non-Adherence Increase Treatment Costs in Schizophrenia?

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

6.  Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.

Authors:  Iglika Vassileva; Vihra Milanova; Turan Asan
Journal:  Community Ment Health J       Date:  2014-01-23

7.  Oral Antipsychotic Versus Long-Acting Injections Antipsychotic in Schizophrenia Spectrum Disorder: a Mirror Analysis in a Real-World Clinical Setting.

Authors:  Nicola Poloni; Marta Ielmini; Ivano Caselli; Giulia Lucca; Alessandra Gasparini; Alessandra Gasparini; Giorgia Lorenzoli; Camilla Callegari
Journal:  Psychopharmacol Bull       Date:  2019-06-20

8.  Time to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies.

Authors:  Rune A Kroken; Eirik Kjelby; Tore Wentzel-Larsen; Liv S Mellesdal; Hugo A Jørgensen; Erik Johnsen
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

Review 9.  Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Authors:  Matt Shirley; Caroline M Perry
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

10.  Development and Feasibility Testing of a Smartphone Intervention to Improve Adherence to Antipsychotic Medications.

Authors:  Julie Kreyenbuhl; Elizabeth J Record; Seth Himelhoch; Melanie Charlotte; Jessica Palmer-Bacon; Lisa B Dixon; Deborah R Medoff; Lan Li
Journal:  Clin Schizophr Relat Psychoses       Date:  2016-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.